Izzar Rachid 4

What Happened
Izzar Rachid, Head of Global Product Strategy at Biogen (BIIB), received a grant of 7,390 restricted stock units (RSUs) on 2026-02-13. The Form 4 lists the acquisition price as $0.00 (code A — award/grant), indicating these are compensation awards rather than a market purchase or sale. No cash changed hands at grant; the RSUs are derivatives that will convert to common shares only as they vest.

Key Details

• Transaction date: 2026-02-13 (Form 4 filed 2026-02-17 — within the normal reporting window).
• Transaction type/code: Award/Grant (A); acquisition price reported as $0.00.
• Number of RSUs granted: 7,390.
• Vesting: RSUs vest in three equal yearly installments beginning on the first anniversary of the grant date (Feb 13, 2026) per the filing footnote.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Filing timeliness: Appears timely (filed four days after the transaction date).

Context
RSU grants are a common form of executive/employee compensation and do not represent an immediate purchase or sale of stock. The economic benefit to the insider depends on Biogen’s share price when each tranche vests and any plan terms (e.g., forfeiture on termination). Such awards signal routine compensation rather than an open-market sentiment trade.